The Immunotherapy Drugs Market is set to grow from USD 257.60 billion in 2024 to USD 486.36 billion by 2030, with a CAGR of ...

The global monoclonal antibodies market is poised for robust expansion, projected to surge from USD 208.32 billion in 2022 to USD 647.01 billion by 2032, reflecting a CAGR of 12% over the forecast ...

The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may ...

As per the latest analysis, the biosimilar and biologics market value is estimated to reach USD 520.9 billion in 2024. Global sales of biosimilars and biologics will likely increase at 7.6% CAGR ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).

Biocon Biologics and Yoshindo expand access to ustekinumab biosimilar in Japan: Our Bureau, Bengaluru Wednesday, May 21, 2025, 15:15 Hrs [IST] Biocon Biologics a fully integrated ...